SUBJECT: Parathion, Acute oral neurotoxicity study in rats

TO: Larry Schnaubelt PM 72
    Reregistration Branch
    Special Review and Reregistration Division (H7508C)

FROM: Robert P. Sendzian Ph.D.
    Senior Pharmacologist
    Toxicology Branch I
    Health Effects Division (H7509C)

THROUGH: Karl Baetcke Ph.D.
    Chief
    Toxicology Branch I
    Health Effects Division (H7509C)

Compound: Parathion
MRID: 431179-01
Registration #: 057501
Registrant: Chem Nova
DP Barcode: D199873

Action Requested

Review the following study:

Citation
Acute neurotoxicity study of ethyl parathion in rats, D.J. Minnema, Hazleton
Washington, HWA 2688-100, Feb 3, 1994, MRID 431179-01

Core Classification Acceptable

Conclusions

Single oral dose of 0, 0.025, 2.5 & 10.0 mg/kg males and 0, 0.025, 0.5 & 2.5
mg/kg females. 2 deaths males 10.0 mg/kg. Significant depression (p>0.05) plasma,
RBC and brain (6 areas) cholinesterase activity males 10.0 and females 2.5 mg/kg
4 hours post dose. 50 to 80% of concurrent controls. Incomplete recovery 14 days
post dose, significant depression (p>0.0) male RBC and brainstem. Functional
observational battery, signs indicative cholinesterase toxicity 4 hours post dose
males 10 and females 2.5 mg/kg. Full recovery day 7. No histopathological lesions
in the nervous system 14 days post dose.
Data Evaluation Report

Compound: Parathion

Citation:
Acute neurotoxicity study of ethyl parathion in rats, D.J.
Minnema, Hazleton Washington, HWA 2688-100, Feb 3, 1994, MRID 431179-01

Reviewed by Robert P. Zendzian PhD
Senior Pharmacologist

Core Classification: Acceptable

Conclusions:
Single oral dose of 0, 0.025, 2.5 & 10.0 mg/kg males and
0, 0.025, 0.5 & 2.5 mg/kg females. 2 deaths males 10.0 mg/kg.
Significant depression (p>0.05) plasma, RBC and brain (6 areas) cholinesterase activity males 10.0 and females 2.5
mg/kg 4 hours post dose. 50 to 80% of concurrent controls.
Incomplete recovery 14 days post dose, significant depression
(p>0.0) male RBC and brainstem. Functional observational
battery, signs indicative cholinesterase toxicity 4 hours
post dose males 10 and females 2.5 mg/kg. Full recovery day
7. No histopathological lesions in the nervous system 14 days
post dose.

Materials:
Ethyl parathion
Batch No 79818-01
brown liquid
purity 86.2%
from Cheminova Agro A/S

Vehicle/control
Duke's® Corn Oil
Lot no 2B25 17:59

Test animals
Male and female Sprague-Dawley Crl:CD®BR rats
approximately 4 weeks old
from Charles River Laboratories
Raleigh NC

Experimental design:

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (mg/kg)</th>
<th>Number of Animals</th>
<th>Neurobehavioral</th>
<th>Cholinesterase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>0.025</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>0.5</td>
<td>0</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>2.5</td>
<td>10</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>10.0</td>
<td>13</td>
<td>0</td>
<td>12</td>
</tr>
</tbody>
</table>
Animals designated for neurobehavioral testing were dosed at approximately seven weeks of age and animals designated for cholinesterase determinations were dosed at approximately eight weeks of age. A single oral dose.

Dosing formulations were prepared in corn oil so that the designated dose was administered orally in 2 milliliter of solution per kilogram body weight. Formulations were prepared separately for dosing the neurobehavioral and cholinesterase animals. Samples were analyzed for parathion content.

Animals were observed for mortality and moribundity twice daily and a through physical examination conducted at each weighing interval. Body weights were obtained at randomization, prior to treatment, day 0, day 7 and day 14.

Cholinesterase

The animals designated for cholinesterase determination were sampled according to the following schedule.

Table 1. Schedule of cholinesterase samples. Blood samples for cholinesterase activity were taken 2 days prior to dosing. Blood and brain were taken for cholinesterase activity on day zero, four hours after dosing, and on day 14. The latter animals were those previously sampled on day -2.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Number of Animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Male</td>
</tr>
<tr>
<td></td>
<td>-2  0  14 Dosing Day</td>
</tr>
<tr>
<td>0</td>
<td>5 &gt;-----&gt; 5</td>
</tr>
<tr>
<td>0.025</td>
<td>5</td>
</tr>
<tr>
<td>0.5</td>
<td>5</td>
</tr>
<tr>
<td>2.5</td>
<td>5</td>
</tr>
<tr>
<td>2.5</td>
<td>5</td>
</tr>
<tr>
<td>10.0</td>
<td>5</td>
</tr>
<tr>
<td>10.0</td>
<td>5 &gt;-----&gt; 5</td>
</tr>
</tbody>
</table>

Blood samples were analyzed for plasma and RBC activity. The brain was removed, divided into six regions and each analyzed for cholinesterase activity. Brain regions were olfactory bulbs, cerebellum, cortex, stratum, hippocampus and midbrain plus brainstem.
Neurobehavioral

"A battery of behavioral tests and observations, referred to as the Functional Observational Battery (FOB), designed to measure various aspects of sensory and motor functions, was conducted on the first 10 or 13 (Group 4 females and Group 5 males) animals/group/sex prior to initiation of dosing, 4 hours after dosing and at least 1 and 2 weeks after dosing. The 4-hour-postdose time interval was provided by the Sponsor and, according to the Sponsor, represented the time of peak neurobehavioral activity of the test material. The FOB was performed during the dark cycle at approximately the same time of the day at each interval. With the exception of the performance measures, all neurobehavioral assessments were conducted under red-light conditions. A detailed description of the criteria for each observation is presented in the following pages." See appendix I pages 23-27 from the report.

Termination

"On the day of scheduled necropsy (at least 15 days after dosing), all animals designated for neurobehavioral observations were weighed and given an intraperitoneal injection of sodium pentobarbital. A whole body perfusion was performed on six rats/sex/group." All of the remaining rats were necropsied. The following tissues from each perfused animal were collected and preserved.

Anterior tibialis muscles
brain with brainstem (medulla/pons, cerebellar cortex and cerebral cortex
cervical dorsal root and ventral root fibers
cervical spinal cord
cervical dorsal root ganglia
eyes with a portion of the optic nerve
gasserian ganglion
gastrocnemious muscles
lumbar dorsal root and ventral root fibers
lumbar spinal cord
lumbar dorsal root ganglia
macroscopic lesions
mid-thoracic spinal cord
pituitary
sciatic nerve
sural nerve
tibial nerve

Histopathology

"With the exception of the proximal sciatic, sural and tibial nerves, all preserved tissues from the perfused animals in the control (Group 1 male and female rats) and high-dose
animals (Group 5 male and group 4 female rats) were impeded in paraffin, sectioned at 5u, mounted and stained with hematoxylin and eosin. The proximal sciatic, sural and tibial nerves were embedded in plastic (glycol methacrylate), cross-sectioned at 1 u, stained with toluidine blue 0, and examined microscopically from all perfused animals in the control and high-dose groups (Group 5 male and Group 4 female rats). In addition, longitudinal sections of the peripheral nerves were embeded in paraffin, sectioned at 5 u, stained with luxol fast blue, and counter stained with periodic acid-Schiff.

Results

Two high dose (10 mg/kg) males died the day of dosing. Signs indicative of cholinesterase poisoning, hypoxia, labored respiration, rough coat, chromodacryorrhoea, urine stains, muscle fasciculations, tremors and salivation, were observed in the remaining males on the day of dosing and continued for 13 days-post dose for one to two males. Similar signs were observed in one high dose (2.5 mg/kg) female on the day of dosing. A significant decrease in weight relative to control was observed in the high dose males (10 mg/kg) on day 7 post dose but not on day 14. No effect on body weight was observed in the females.

Results of cholinesterase determinations are presented in Table 5 from the report. Results as percent of concurrent control have been calculated by the reviewer. A dose of 2.5 mg/kg parathion produced significant depression in plasma and RBC cholinesterase activity (p>0.05) 4 hours post dose in both sexes. Recovery, partial to full, was observed at 14 days post dose, but the RBC activity in the males at 10 mg/kg remained significantly depressed (p>0.05).

In effect on the brain, the female was more sensitive then the male at four hours post dose. A dose of 2.5 mg/kg (HDT) in the female produced a significant reduction of activity (p>0.05) in all six brain areas tested but no apparent effect was observed in the males at this dose. A significant reduction of brain activity (p>0.05) was observed at 10 mg/kg (HDT) in the males. Brain activity, in both sexes, showed a variable but incomplete degree of recovery by day 14 post dose. However, only the male brainstem showed significant depression (p>0.05).

Mild changes in FOB compared to pretreatment and concurrent controls were observed at 4 hours post dose which could be attributed to treatment in the males at 10 mg/kg (HDT) and the females at 2.5 mg/kg (HDT). All treated animals were normal at 7 and 14 days post dose. See appendix II.

No treatment related effects were observed at histopathological examination.
Page____ is not included in this copy.
Pages 9 through 11 are not included.

The material not included contains the following type of information:

___ Identity of product inert ingredients.
___ Identity of product impurities.
___ Description of the product manufacturing process.
___ Description of quality control procedures.
___ Identity of the source of product ingredients.
___ Sales or other commercial/financial information.
___ A draft product label.
___ The product confidential statement of formula.

Information about a pending registration action.

√ FIFRA registration data.

___ The document is a duplicate of page(s) ______.
___ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
<table>
<thead>
<tr>
<th>Study/Lab/Study #/Date</th>
<th>Material</th>
<th>EPA MRID No.</th>
<th>Results: LDS0, LC50, PIS, NOEL, LEL</th>
<th>TOX Category</th>
<th>CORE Grade/Doc. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute neurotoxicity, Rat; Hazleton Wash, IMA 2688-100; 2/3/94</td>
<td>tech 86.2%</td>
<td>431179-01</td>
<td>Single oral dose of 0, 0.025, 2.5 &amp; 10.0 mg/kg males and 0, 0.025, 0.5 &amp; 2.5 mg/kg females. 2 deaths males 10.0 mg/kg. Significant depression (p&gt;0.05) plasma, RBC and brain (6 areas) cholinesterase activity males 10.0 and females 2.5 mg/kg 4 hours post dose. 50 to 80% of concurrent controls. Incomplete recovery 14 days post dose. Significant depression (p&gt;0.0) male RBC and brainstem. Functional observational battery, signs indicative cholinesterase toxicity 4 hours post dose males 10 and females 2.5 mg/kg. Full recovery day 7. No histopathological lesions in the nervous system 14 days post dose.</td>
<td>N/A</td>
<td>Acceptable</td>
</tr>
</tbody>
</table>
Page 15 is not included in this copy.
Pages 15 through 29 are not included.

The material not included contains the following type of information:

___ Identity of product inert ingredients.
___ Identity of product impurities.
___ Description of the product manufacturing process.
___ Description of quality control procedures.
___ Identity of the source of product ingredients.
___ Sales or other commercial/financial information.
___ A draft product label.
___ The product confidential statement of formula.
___ Information about a pending registration action.
___ FIFRA registration data.
___ The document is a duplicate of page(s) ______.
___ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.